Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1-refractory melanoma
The phase II randomized, cooperative group trial SWOG S1616 (NCT03033576) demonstrated that patients with advanced melanoma who did not respond to front line PD-1/L1 blockade therapy had improved progression free survival and objective response rates with the combination of ipilimumab with nivolumab compared to ipilimumab monotherapy, thereby reversing primary resistance to PD-1 blockade in a subset of patients receiving the combination therapy. This project includes the DNA and RNA sequencing data generated from tumor biopsies and DNA sequencing data generated from peripheral blood collected from patients enrolled in SWOG S1616.